It’s a jungle out there. Deriving the right royalty rate for new pharmaceuticals and biotechnologies is a real tangle. This is a critical business function, and it has never been more important ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners ... company hopes to recover a “reasonable royalty” tied to Moderna’s vaccine sales ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the ...

(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net profit of 198.1 million euros or 0.81 euros per share for the third quarter ...

He wrote: “I got to meet the new British Rock Royalty tonight – The Last Dinner Party – and they completely smashed it tonight at the Eventim Apollo. What a great show! What a joy!!!

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last ...

Welcome to The HELLO! Royal Club, where thousands of royal fans like you get to delve deeper into the wonderful world of royalty every day. Want to join them? Just click the button below for a ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...